FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.
Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.
We haven't written up this one. MarketWatch Top has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.